Literature DB >> 34089257

Low Serum Tumor Necrosis Factor-α Antagonist Concentrations in Patients With Inflammatory Bowel Disease Who Achieve Healing From Pyoderma Gangrenosum.

Maria Mikail1, Aze Wilson1,2,3,4.   

Abstract

Entities:  

Keywords:  pyoderma gangrenosum; tumor necrosis factor-α antagonists

Mesh：

Substances：

Year:  2021        PMID： 34089257      PMCID： PMC8562473          DOI： 10.1093/ibd/izab148

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   7.290


× No keyword cloud information.
  5 in total

Review 1.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Authors:  Joseph D Feuerstein; Geoffrey C Nguyen; Sonia S Kupfer; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-08-03       Impact factor: 22.682

2.  Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.

Authors:  A J Yarur; V Kanagala; D J Stein; F Czul; M A Quintero; D Agrawal; A Patel; K Best; C Fox; K Idstein; M T Abreu
Journal:  Aliment Pharmacol Ther       Date:  2017-02-17       Impact factor: 8.171

Review 3.  Effective strategies for the management of pyoderma gangrenosum: a comprehensive review.

Authors:  Forum Patel; Sarah Fitzmaurice; Christopher Duong; Young He; Jonathan Fergus; Siba P Raychaudhuri; Miki Shirakawa Garcia; Emanual Maverakis
Journal:  Acta Derm Venereol       Date:  2015-05       Impact factor: 4.437

Review 4.  Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment.

Authors:  Afsaneh Alavi; Lars E French; Mark D Davis; Alain Brassard; Robert S Kirsner
Journal:  Am J Clin Dermatol       Date:  2017-06       Impact factor: 7.403

Review 5.  Extraintestinal Manifestations of Inflammatory Bowel Disease.

Authors:  Stephan R Vavricka; Alain Schoepfer; Michael Scharl; Peter L Lakatos; Alexander Navarini; Gerhard Rogler
Journal:  Inflamm Bowel Dis       Date:  2015-08       Impact factor: 5.325
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.